Pfizer, Voyager Therapeutics ink USD 630 million gene therapy deal

Under the terms of the agreement, Pfizer will have the right to evaluate novel capsids selected for central nervous system and cardiac tropisms from Voyager's TRACER platform and to exercise options...

Related Keywords

United States ,American ,Tseng Cheng ,Michael Higgins ,Pfizer ,Pfizer Rare Disease Research Unit ,Meeting Of The American Society Gene ,Tropism Redirection ,Cell Type Specific Expression ,Senior Vice President ,Chief Scientific Officer ,Rare Disease Research ,Annual Meeting ,American Society ,Cell Therapy ,Tracer Platform ,Voyager Therapeutics ,Gene Therapy ,Adeno Associated Virus Platform Technologies ,Maav ,Tracer Aav Capsids ,Neurologic Gene Therapy ,Cardiovascular Gene Therapy ,Tracer Tm ,Tracer Technology ,